Cobitolimod

Drug Profile

Cobitolimod

Alternative Names: Antisense oligonucleotide NF-KB-p65; DIMS 0150; Kappaproct

Latest Information Update: 04 Nov 2016

Price : $50

At a glance

  • Originator InDex Pharmaceuticals
  • Class Antisense oligonucleotides
  • Mechanism of Action Genetic transcription modulators; NF-kappa B inhibitors; Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ulcerative colitis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Ulcerative colitis
  • Phase I Brain oedema

Most Recent Events

  • 03 Nov 2016 InDex Pharmaceuticals has patent protection for cobitolimod in USA
  • 03 Nov 2016 InDex Pharmaceuticals has patents pending for cobitolimod in Europe, Japan and Canada
  • 18 Oct 2016 Post-hoc analysis from the phase III COLLECT trial in Ulcerative colitis released by InDex Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top